The article is primarily an analyst note/price target change (bullish) tied to the Apogee deal narrative, which can influence near-term sentiment and positioning, though it’s not a direct company earnings/product release.
Canaccord Says AbbVie’s (ABBV) Apogee Deal Strengthens Long-Term Growth Outlook Vardah Gill Thu, June 25, 2026 at 5:35 AM GMT+2 2 min read ABBV APGE AbbVie Inc. (NYSE: ABBV ) is included among the Top 10 Blue Chip Stocks with Growing Dividends . Canaccord Says AbbVie's (ABBV) Apogee Deal Strengthens Long-Term Growth Outlook On June 23, Canaccord raised its price recommendation on AbbVie Inc.
(NYSE:ABBV) to $273 from $265. It reiterated a Buy rating on the shares. The firm updated its model following AbbVie's announced acquisition of Apogee Therapeutics (APGE).
Canaccord said the deal makes strong strategic sense, as it adds a potential mega-blockbuster immunology asset targeting atopic dermatitis (AD) and asthma. The firm believes the asset could become a major growth driver for AbbVie over the next decade. On June 22, Wells Fargo maintained an Overweight rating on AbbVie.
It also set a $260 price target on the stock. In a research note, the firm said AbbVie's reported bid for Apogee Therapeutics is logical because Apogee scores highly on its M&A screening framework. Wells Fargo told investors that such a transaction would likely be viewed positively by the market and could support AbbVie's shares.
The firm also noted that the deal could create pressure on Regeneron by increasing competition in the space. AbbVie Inc. (NYSE:ABBV) is a global, diversified, research-based biopharmaceutical company.
The company focuses on the research and development, manufacturing, commercialization, and sale of medicines and therapies. While we acknowledge the potential of ABBV as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock .
READ NEXT: Top 11 Dividend Kings to Buy for Safe Dividend Growth and Billionaire Mario Gabelli's Top 12 Dividend Stocks Disclosure: None. Follow Insider Monkey on Google News .
Oraklio AI Trading Intelligence
Oraklio turns news, price data, and market signals into structured BUY / SELL / NO_TRADE calls - updated continuously throughout the trading day.
Get started freeAlready have an account? Sign in →